Email Updates

You are here

Home

MTN-039

Status
Ongoing
Phase
Open Label
I
Objective

A Phase 1 Open Label Safety and Pharmacokinetic Study of Single Dose Rectal Administration of an Elvitegravir Insert at Two Dose Levels

 

Last Updated May 3, 2021

Prevention Option(s)
Microbicides
Multipurpose Prevention Technologies
Arms and Assigned Interventions
Description
TAF/EVG Insert (20/16 mg) administered rectally by study staff
Mode of Delivery
Tablet
Products
Elvitegravir (EVG)
ARMs
Experimental
Official Code
NCT04047420
Trial Sponsors
MTN
December 2019
March 2021
Enrollment
20
18
Years
Population
Men
Women
Sites

Alabama Microbicide CRS

Birmingham, Alabama
United States of America

University of Pittsburgh CRS

Pittsburgh, Pennsylvania
United States of America